Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HPGD | P15428 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | TP53 | P04637 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | DUSP1 | P28562 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4361940 | 0.89 | SMN1; SMN2 (1.00) | ALDH1A1HPGDSMN1; SMN2TP53RAB9A | |
| SCHEMBL5993312 | 0.75 | MAPT (0.67) | ALDH1A1SMN1; SMN2TP53RAB9ANPC1 | |
| SCHEMBL14096436 | 0.75 | NPC1 (0.62) | ALDH1A1HPGDSMN1; SMN2TP53RAB9A | |
| SCHEMBL14096650 | 0.73 | NPC1 (0.67) | ALDH1A1HPGDSMN1; SMN2TP53RAB9A | |
| SCHEMBL14096127 | 0.73 | MAPT (0.61) | ALDH1A1HPGDSMN1; SMN2TP53RAB9A | |
| SCHEMBL14096079 | 0.72 | MAPT (0.78) | ALDH1A1SMN1; SMN2TP53RAB9ANPC1 | |
| SCHEMBL19748087 | 0.72 | PCSK9 (1.00) | ALDH1A1HPGDSMN1; SMN2TP53RAB9A | |
| SCHEMBL31631288 | 0.71 | RAB9A (0.70) | ALDH1A1HPGDSMN1; SMN2TP53RAB9A | |
| SCHEMBL10144144 | 0.70 | MAPT (0.67) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| SCHEMBL25674719 | 0.70 | DUSP1 (0.65) | ALDH1A1HPGDSMN1; SMN2TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | ALDH1A1 2930/4885HPGD 919/4885SMN1; SMN2 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.